For investors

AbilityPharma shareholders include the venture capital firm Inveready, private investors and the founders of the company.
 
The company has obtained grants from high level public institutions:
 
  • NEBT grant from ACCIÓ, Government of Catalonia.
  • Technological Innovation Nuclei grant from ACCIÓ, Government of Catalonia.
  • PID from CDTI, Government of Spain.
  • Innocash from Fundación Genoma España, Government of Spain.
  • ENISA (National Innovation Company), Ministry of Industry, Energy and Tourism, Government of Spain.
  • Investment Readiness program from ACC1Ó, Government of Catalonia.
  • Torres-Quevedo grants from CDTI, Government of Spain.
  • International Talent grant from Biocat (Bioregion Catalonia), Government of Catalonia.
  • Inncorpora grant from the Ministry of Economy and Competitivity, Government of Spain.
  • Innpacto grants from the Ministry of Economy and Competitivity, Government of Spain.
  • Retos grants from the Ministry of Economy and Competitivity, Government of Spain.

 

http://www.biocat.cat/sites/all/themes/biocat/images/Logo_Biocat_RGB.jpg

 

 

LATEST NEWS

05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits